The complement system in central nervous system diseases

Horea Rus, Cornelia Cudrici, Stefan David, Florin Niculescu

Research output: Contribution to journalArticle

Abstract

The activation of complement system is important factor in inflammatory, neurodegenerative and cerebrovascular diseases. CNS cells are able to synthesize complement components, and myelin and oligodendrocytes (OLG) are known to activate the classical pathway of complement in vitro in the absence of antibodies. Although activation of the complement system is known to promote tissue injury, recent evidence has also indicated that this process can have neuroprotective effects. In particular, terminal C5b-9 complexes enhance OLG survival both in vitro and in vivo. Complement activation may also reduce the accumulation of amyloid and degenerating neurons by promoting their clearance and suggest that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease. Complement system activation plays also an important role in brain damage after ischemic injury or head trauma. These findings strongly suggest that complement activation and membrane assembly of C5b-9 can play a role in injury but can also provide neuroprotection depending on the pathophysiological context.

Original languageEnglish (US)
Pages (from-to)395-402
Number of pages8
JournalAutoimmunity
Volume39
Issue number5
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Complement Activation
Central Nervous System Diseases
Complement Membrane Attack Complex
Oligodendroglia
Neurodegenerative Diseases
Wounds and Injuries
Classical Complement Pathway
Cerebrovascular Disorders
Brain
Neuroprotective Agents
Myelin Sheath
Craniocerebral Trauma
Amyloid
Neurons
Membranes
Antibodies
In Vitro Techniques

Keywords

  • C5b-9
  • Complement activation
  • Demyelination
  • Neurodegeneration
  • Oligodendrocytes
  • Stroke

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Rus, H., Cudrici, C., David, S., & Niculescu, F. (2006). The complement system in central nervous system diseases. Autoimmunity, 39(5), 395-402. https://doi.org/10.1080/08916930600739605

The complement system in central nervous system diseases. / Rus, Horea; Cudrici, Cornelia; David, Stefan; Niculescu, Florin.

In: Autoimmunity, Vol. 39, No. 5, 08.2006, p. 395-402.

Research output: Contribution to journalArticle

Rus, H, Cudrici, C, David, S & Niculescu, F 2006, 'The complement system in central nervous system diseases', Autoimmunity, vol. 39, no. 5, pp. 395-402. https://doi.org/10.1080/08916930600739605
Rus, Horea ; Cudrici, Cornelia ; David, Stefan ; Niculescu, Florin. / The complement system in central nervous system diseases. In: Autoimmunity. 2006 ; Vol. 39, No. 5. pp. 395-402.
@article{c6f82320459248559300fbf8e4973277,
title = "The complement system in central nervous system diseases",
abstract = "The activation of complement system is important factor in inflammatory, neurodegenerative and cerebrovascular diseases. CNS cells are able to synthesize complement components, and myelin and oligodendrocytes (OLG) are known to activate the classical pathway of complement in vitro in the absence of antibodies. Although activation of the complement system is known to promote tissue injury, recent evidence has also indicated that this process can have neuroprotective effects. In particular, terminal C5b-9 complexes enhance OLG survival both in vitro and in vivo. Complement activation may also reduce the accumulation of amyloid and degenerating neurons by promoting their clearance and suggest that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease. Complement system activation plays also an important role in brain damage after ischemic injury or head trauma. These findings strongly suggest that complement activation and membrane assembly of C5b-9 can play a role in injury but can also provide neuroprotection depending on the pathophysiological context.",
keywords = "C5b-9, Complement activation, Demyelination, Neurodegeneration, Oligodendrocytes, Stroke",
author = "Horea Rus and Cornelia Cudrici and Stefan David and Florin Niculescu",
year = "2006",
month = "8",
doi = "10.1080/08916930600739605",
language = "English (US)",
volume = "39",
pages = "395--402",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - The complement system in central nervous system diseases

AU - Rus, Horea

AU - Cudrici, Cornelia

AU - David, Stefan

AU - Niculescu, Florin

PY - 2006/8

Y1 - 2006/8

N2 - The activation of complement system is important factor in inflammatory, neurodegenerative and cerebrovascular diseases. CNS cells are able to synthesize complement components, and myelin and oligodendrocytes (OLG) are known to activate the classical pathway of complement in vitro in the absence of antibodies. Although activation of the complement system is known to promote tissue injury, recent evidence has also indicated that this process can have neuroprotective effects. In particular, terminal C5b-9 complexes enhance OLG survival both in vitro and in vivo. Complement activation may also reduce the accumulation of amyloid and degenerating neurons by promoting their clearance and suggest that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease. Complement system activation plays also an important role in brain damage after ischemic injury or head trauma. These findings strongly suggest that complement activation and membrane assembly of C5b-9 can play a role in injury but can also provide neuroprotection depending on the pathophysiological context.

AB - The activation of complement system is important factor in inflammatory, neurodegenerative and cerebrovascular diseases. CNS cells are able to synthesize complement components, and myelin and oligodendrocytes (OLG) are known to activate the classical pathway of complement in vitro in the absence of antibodies. Although activation of the complement system is known to promote tissue injury, recent evidence has also indicated that this process can have neuroprotective effects. In particular, terminal C5b-9 complexes enhance OLG survival both in vitro and in vivo. Complement activation may also reduce the accumulation of amyloid and degenerating neurons by promoting their clearance and suggest that certain inflammatory defense mechanisms in the brain may be beneficial in neurodegenerative disease. Complement system activation plays also an important role in brain damage after ischemic injury or head trauma. These findings strongly suggest that complement activation and membrane assembly of C5b-9 can play a role in injury but can also provide neuroprotection depending on the pathophysiological context.

KW - C5b-9

KW - Complement activation

KW - Demyelination

KW - Neurodegeneration

KW - Oligodendrocytes

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=33747654425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747654425&partnerID=8YFLogxK

U2 - 10.1080/08916930600739605

DO - 10.1080/08916930600739605

M3 - Article

C2 - 16923539

AN - SCOPUS:33747654425

VL - 39

SP - 395

EP - 402

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 5

ER -